OKYO Pharma Ltd (OKYO) ORD NPV

Sell:$2.52Buy:$2.75$0.03 (0.99%)

Prices delayed by at least 15 minutes
Sell:$2.52
Buy:$2.75
Change:$0.03 (0.99%)
Prices delayed by at least 15 minutes
Sell:$2.52
Buy:$2.75
Change:$0.03 (0.99%)
Prices delayed by at least 15 minutes

Company Information

About this company

OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Key people

Gary S. Jacob
Chief Executive Officer, Executive Director
Keeren Shah
Chief Financial Officer
Raj Patil
Chief Scientific Officer
Gabriele Marco Antonio Cerrone
Non-Executive Chairman of the Board
Willy Jules Simon
Senior Non-Executive Director
John P. Brancaccio
Non-Executive Independent Director
Bernard F. Denoyer
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    OKYO
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GG00BMFG5F62
  • Market cap
    $95.34m
  • Employees
    4
  • Shares in issue
    37.61m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.